Brii Biosciences (HKG:2137) posted a loss attributable to owners of 222.6 million yuan for 2025, narrowing from 508.2 million yuan a year earlier, according to a Thursday Hong Kong bourse filing.
Shares of the drug company were down over 6% in Friday morning trade.
Loss per share came in at 0.31 yuan, compared with a loss of 0.70 yuan a year earlier.
Revenue was 18.6 million yuan from nil in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.